AWAKN SELECTS EUROFINS DISCOVERY FOR PHARMACOLOGY TESTING IN NEW CHEMICAL ENTITY (NCE) PRE-CLINICAL PROGRAM
Toronto, Canada – October, 04, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics for…